The therapeutic potential of Nrf2 inducers in chronic pain: Evidence from preclinical studies

Chronic pain remains an enormous health problem affecting approximatively 30% of the world's population. Opi-oids as the first line analgesics often leads to undesirable side effects when used long term. Therefore, novel ther-apeutic targets are urgently needed to the development of more efficacious analgesics. Substantial evidence indicates that excessive reactive oxygen species (ROS) are extremely important to the development of chronic pain. Nuclear factor erythroid 2-related factor 2 (Nrf 2) isa master transcription factor regulating endogenous an-tioxidant defense. Emerging evidence suggests that Nrf 2 and its downstream effectors are implicated in chronic inflammatory and neuropathic pain. Notably, controversial results have been reported regarding the expression of Nrf2 and its downstream targets in peripheral and central regions involved in pain transmission. However, our recent studies and results from other laboratories demonstrate that Nrf 2 inducers exert potent analgesic effects in various murine models of chronic pain. In this review, we summarized and discussed the preclinical evidence demonstrating the therapeutic potential of Nrf 2 inducers in chronic pain. These evidence indicates that Nrf2 activation are beneficial in chronic pain mostly by alleviating ROS-associated pathological processes. Overall, Nrf 2-based therapy for chronic pain is an area with great promise, but more research regarding its detailed mechanisms is warranted. (c) 2021 Elsevier Inc. All rights reserved.